Given these, our work provides deep insight into the biochemical inhibition of the protein leucine-rich repeat kinase 2 (LRRK2), linked to familial and sporadic cases of PD and to the pathways regulating inflammation of the CNS. This evidence concerns the gene LRRK2 and Parkinson disease.